AU2003259759A1 - Gal3 receptor antagonists for the treatment of affective disorders - Google Patents

Gal3 receptor antagonists for the treatment of affective disorders

Info

Publication number
AU2003259759A1
AU2003259759A1 AU2003259759A AU2003259759A AU2003259759A1 AU 2003259759 A1 AU2003259759 A1 AU 2003259759A1 AU 2003259759 A AU2003259759 A AU 2003259759A AU 2003259759 A AU2003259759 A AU 2003259759A AU 2003259759 A1 AU2003259759 A1 AU 2003259759A1
Authority
AU
Australia
Prior art keywords
treatment
receptor antagonists
affective disorders
gal3 receptor
gal3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003259759A
Inventor
Thomas P. Blackburn
Michael Konkel
John M. Wetzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synaptic Pharmaceutical Corp
Original Assignee
Synaptic Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synaptic Pharmaceutical Corp filed Critical Synaptic Pharmaceutical Corp
Publication of AU2003259759A1 publication Critical patent/AU2003259759A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
AU2003259759A 2002-08-07 2003-08-07 Gal3 receptor antagonists for the treatment of affective disorders Abandoned AU2003259759A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21534602A 2002-08-07 2002-08-07
US10/215,346 2002-08-07
PCT/US2003/025133 WO2004014376A1 (en) 2002-08-07 2003-08-07 Gal3 receptor antagonists for the treatment of affective disorders

Publications (1)

Publication Number Publication Date
AU2003259759A1 true AU2003259759A1 (en) 2004-02-25

Family

ID=31714270

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003259759A Abandoned AU2003259759A1 (en) 2002-08-07 2003-08-07 Gal3 receptor antagonists for the treatment of affective disorders

Country Status (2)

Country Link
AU (1) AU2003259759A1 (en)
WO (1) WO2004014376A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642281B2 (en) 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
KR20080077646A (en) * 2005-12-09 2008-08-25 헬리콘 테라퓨틱스 인코퍼레이티드 Indolone compounds useful to treat cognitive impairment
US8277842B1 (en) 2012-01-20 2012-10-02 Dart Neuroscience (Cayman) Ltd. Enteric-coated HT-2157 compositions and methods of their use
CN104903312B (en) * 2013-10-07 2019-01-29 卡德门企业有限公司 RHO kinase inhibitor
CN108191774B (en) * 2018-01-31 2022-05-24 中国药科大学 Heterocyclic compound, preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329197B2 (en) * 1996-10-09 2001-12-11 Synaptic Pharmaceutical Corporation DNA encoding galanin GALR3 receptors and uses thereof
WO2002060392A2 (en) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

Also Published As

Publication number Publication date
WO2004014376A1 (en) 2004-02-19

Similar Documents

Publication Publication Date Title
AU2003286567A1 (en) Methods for the treatment of skin disorders
PL372425A1 (en) Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
AU2003249983A1 (en) Piperidines useful for the treatment of central nervous system disorders
EP1556047A4 (en) Pgd2 receptor antagonists for the treatment of inflammatory diseases
AU2003228819A1 (en) Combinations for the treatment of inflammatory skin disorders
AU2003291719A1 (en) Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
AU2003286728A1 (en) Compounds for the treatment of metabolic disorders
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
HK1080859A1 (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
EP1709196A4 (en) Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders
AU2003259759A1 (en) Gal3 receptor antagonists for the treatment of affective disorders
AU2003259074A1 (en) Gal3 antagonists for the treatment of neuropathic pain
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
HRP20041160A2 (en) Novel combination for the treatment of airway disorders
AU2003273856A1 (en) Vr1 antagonists for the treatment of urological disorders
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
AU2002339673A1 (en) Agonists and antagonists of ryzn for the treatment of metabolic disorders
AU2003243214A1 (en) Salts of bis-arylsulfones for the treatment of cns disorders
AU2003245995A1 (en) Use of gaba-c receptor antagonists for the treatment of myopia
HRP20041159A2 (en) Combination for the treatment of airway disorders
AU2003300867A8 (en) Uses of the snorf207 receptor
PL374077A1 (en) Use of 5-ht2 receptor antagonists for the treatment of sleep disorders
AU2003254447A1 (en) Treatment of proliferative disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase